Tacalcitol: Difference between revisions
Created page with "<languages /> <translate> {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 376121485 | IUPAC_name = (1''S'',3''R'',5''Z'',7''E'',24''R'')-9,10-secocholesta-5,7,10-triene-1,3,24-triol | image = Tacalcitol.svg <!--Clinical data--> | tradename = | Drugs.com = {{drugs.com|international|tacalcitol}} | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D /..." |
Marked this version for translation |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
<translate> | <translate> | ||
<!--T:1--> | |||
{{Short description|Chemical compound}} | {{Short description|Chemical compound}} | ||
{{Drugbox | {{Drugbox | ||
| Line 9: | Line 10: | ||
| image = Tacalcitol.svg | | image = Tacalcitol.svg | ||
<!--T:2--> | |||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
| Line 22: | Line 24: | ||
| routes_of_administration = Topical | | routes_of_administration = Topical | ||
<!--T:3--> | |||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
| Line 29: | Line 32: | ||
| excretion = | | excretion = | ||
<!--T:4--> | |||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number_Ref = {{cascite|correct|??}} | | CAS_number_Ref = {{cascite|correct|??}} | ||
| Line 46: | Line 50: | ||
| ChemSpiderID = 4446823 | | ChemSpiderID = 4446823 | ||
<!--T:5--> | |||
<!--Chemical data--> | <!--Chemical data--> | ||
| C=27 | H=44 | O=3 | | C=27 | H=44 | O=3 | ||
| Line 56: | Line 61: | ||
}} | }} | ||
<!--T:6--> | |||
'''Tacalcitol''' (1,24-dihydroxyvitamin D<sub>3</sub>) is a synthetic [[vitamin D3|vitamin D<sub>3</sub>]] analog. Tacalcitol is marketed under several names, including '''Curatoderm''' and '''Bonalfa'''. | '''Tacalcitol''' (1,24-dihydroxyvitamin D<sub>3</sub>) is a synthetic [[vitamin D3|vitamin D<sub>3</sub>]] analog. Tacalcitol is marketed under several names, including '''Curatoderm''' and '''Bonalfa'''. | ||
<!--T:7--> | |||
It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | ||
<!--T:8--> | |||
==Mechanism== | ==Mechanism== | ||
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with [[vitamin D receptor]]s on [[keratinocytes]]. | Tacalcitol reduces excessive cell turnover in the epidermis by interacting with [[vitamin D receptor]]s on [[keratinocytes]]. | ||
<!--T:9--> | |||
==Uses== | ==Uses== | ||
It is usually prescribed by a general practitioner or dermatologist for the treatment of [[psoriasis]], chronic [[chapped lips]] and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. | It is usually prescribed by a general practitioner or dermatologist for the treatment of [[psoriasis]], chronic [[chapped lips]] and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion. | ||
<!--T:10--> | |||
It has also been used for [[vitiligo]] and [[Hailey-Hailey disease]]. | It has also been used for [[vitiligo]] and [[Hailey-Hailey disease]]. | ||
<!--T:11--> | |||
{{Antipsoriatics}} | {{Antipsoriatics}} | ||
{{Vitamin D receptor modulators}} | {{Vitamin D receptor modulators}} | ||
<!--T:12--> | |||
{{二次利用|date=11 February 2024}} | {{二次利用|date=11 February 2024}} | ||
[[Category:Secosteroids]] | [[Category:Secosteroids]] | ||